NEWCO PHARMA LIMITED
Company number SC057293 · Monitor this company
This analysis was written by an AI from the company's public filings. It may contain errors or omissions and is not financial or professional advice.
Investment Risk Analysis: NEWCO PHARMA LIMITED
1. Risk Rating: HIGH
Justification: The company has had zero net assets for at least ten consecutive years, is confirmed as no longer trading, and presents an inconsistent ownership structure in its PSC filings. While the entity remains solvent in a technical sense (no net liabilities), the complete absence of shareholder value over a sustained period, combined with non-trading status, presents significant concerns for any investor evaluating this company as a going concern.
2. Key Concerns
a) Zero Net Worth Persistent Over a Decade Shareholders' funds have remained exactly £0 for every year from 2016 to 2025. The balance sheet shows share capital of £5,010 perfectly offset by accumulated losses of (£5,010). This static position over ten years strongly suggests the company is effectively dormant or a shell entity with no operational purpose, despite still reporting 2 employees.
b) Non-Trading Status Confirmed The filed accounts explicitly state the designation "EntityNoLongerTradingButTradedInPast." This is a critical disclosure indicating the company has ceased its core business activity (wholesale of pharmaceutical goods). The income statement has not been delivered to Companies House, which is permitted under Section 444 for small entities but eliminates visibility into any revenue, costs, or trading activity.
c) Inconsistent PSC Ownership Data The PSC register lists three entries: Munro Healthcare Group Limited (owns >75% of shares) and Strathclyde Pharmaceuticals Limited (appears twice, each claiming >75% ownership). It is mathematically impossible for two entities to each hold more than 75% of shares. This inconsistency raises questions about the accuracy of the PSC register and whether proper governance controls are in place for ownership reporting.
3. Positive Indicators
a) Filing Compliance Accounts and confirmation statements are filed on time with no overdue items. The company engaged Bannerman Johnstone Maclay, a firm of chartered accountants, to prepare its financial statements, suggesting some level of professional oversight.
b) Group Structure Backing The ultimate controlling party is identified as Munro Healthcare Group Limited, which may provide financial support or a strategic rationale for maintaining this entity within the group structure, even if non-trading.
c) Long Corporate History Incorporated in 1975, the company has operated for nearly 50 years, indicating it was once a viable trading business under its former name (Strathclyde Pharmaceuticals Limited until 2013).
4. Due Diligence Notes
| Item | Investigation Required |
|---|---|
| PSC Discrepancy | Clarify the true ownership structure. Request the full register of members to confirm actual shareholdings. The duplicate Strathclyde Pharmaceuticals entry may be an administrative error, but this must be verified. |
| Parent Company Financials | Obtain and review the accounts of Munro Healthcare Group Limited to understand the group's overall financial health and the strategic purpose of maintaining this non-trading subsidiary. |
| Intercompany Balances | The balance sheet shows zero net assets but provides no breakdown of assets and liabilities. Determine whether there are intercompany receivables/payables with group entities that could create hidden obligations. |
| Employee Status | The company reports 2 employees despite being non-trading. Clarify whether these are active employees, their roles, and any associated payroll liabilities. |
| Registered Office Discrepancy | The Companies House overview lists Unit 19, Arx House, James Watt Avenue, while the filed accounts list 3 Young Place, Kelvin Industrial Estate. Verify the current registered office and whether this reflects a recent move or an error. |
| Future Intentions | Determine from the parent company whether this entity is being retained for a specific purpose (e.g., holding regulatory licences, intellectual property) or is being wound down. |
| Name Change Context | Investigate the 2013 name change from Strathclyde Pharmaceuticals Limited to Newco Pharma Limited, which coincides with or precedes the cessation of trading. This may indicate a restructuring or acquisition by the Munro Healthcare Group. |